Drug Profile
GDA 201
Alternative Names: GDA-201; NAM NK cells - Gamida; NAM-NK Cells; Nicotinamide Expanded Haploidentical or Mismatched Related Donor Natural Killer CellsLatest Information Update: 15 Mar 2024
Price :
$50
*
At a glance
- Originator Gamida-Cell
- Developer Gamida-Cell; University of Minnesota
- Class Antineoplastics; Cell therapies; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Non-Hodgkin's lymphoma
- No development reported Multiple myeloma; Solid tumours
Most Recent Events
- 23 Feb 2024 Efficacy data from a phase I/II trial in Non-Hodgkin's lymphoma released by Gamida Cell
- 16 Oct 2023 Efficacy and adverse events data form phase I/II clinical trials in Non-Hodgkin's lymphoma released by Gamida Cell
- 18 Feb 2023 Updated pharmacodynamics data from a phase I trial in Non-Hodgkin's lymphoma released by Gamida Cell